This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

X-Change Corporation And Newly-Appointed Senior Medical Advisor Steven B. Hopping, M.D., F.A.C.S., Enter Discussions On Developing A High-End Skincare Product Line

Stocks in this article: XCHC

DALLAS, Feb. 12, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is hemp extract-based cosmeceutical and nutraceutical solutions through its Phytiva brand product line, is in discussions with its newly-appointed Senior Medical Advisor, Steven B. Hopping, M.D., F.A.C.S., to expand the Company's skincare offerings to include a new retail product line.  Dr. Hopping has years of experience promoting and selling top quality private label skincare products under his name.  The Company and Dr. Hopping are considering expanding their respective product lines to meet the increasing demand for affordable, high-end, anti-aging and therapeutic skin care treatments.  With the rapidly growing awareness among women and men of all ages that quality formulations enhance skin health and appearance, the Company believes that consumers in the United States and around the world would welcome an economical and high-quality choice in the existing skincare and skin health marketplace.

Chad Johnson, Chief Operating Officer of X-Change Corp., stated, "The real potential of establishing a skincare line through collaboration between Dr. Hopping and the Company is an exciting development.  Dr. Hopping's well-known expertise in the care of skin health and appearance, combined with the Company's commitment to innovations in the skincare market, are a perfect fit.  We look forward to a continued dialogue with Dr. Hopping with the intention of reaching agreement on a new and innovative line of products to offer consumers nationally and internationally."

About Steven B. Hopping, M.D., F.A.C.S.

Dr. Steven B. Hopping received his specialty training at Harvard University and has been practicing cosmetic surgery for over 20 years, assisting patients across the United States and around the world.  Dr. Hopping is Board Certified by three separate surgical boards: The American Board of Cosmetic Surgery, The American Board of Facial Plastic and Reconstructive Surgery, and The American Board of Otolaryngology, Head and Neck Surgery. He is also a Diplomate of the American Board of Hair Restoration. Dr. Hopping is the Medical Director of The Center for Cosmetic Surgery and of the Washington Hair Institute in Washington, DC .  He also has an active practice in Dubai.  Dr. Hopping is a Clinical Professor of Surgery at George Washington University and is regarded by his peers as a highly talented and innovative cosmetic surgeon. He lectures at numerous national and international conferences each year and is recognized around the world as both a leader and innovator in the cosmetic sector.  Dr. Hopping has written numerous articles and been published in medical journals related to advances in cosmetic surgery, and is frequently sought out by the media as an authority in his field. 

About X-Change Corp., Phytiva, and New Ventures

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs